Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
- Conditions
- Secondary-progressive Multiple SclerosisMotor DeficitsCognitive DeficitsRelapsing Remitting Multiple Sclerosis
- Interventions
- Device: tDCS
- Registration Number
- NCT02266121
- Lead Sponsor
- University Hospital of Mont-Godinne
- Brief Summary
Noninvasive brain stimulations (NIBS) will be used in MS patients with cognitive impairments to enhance their cognitive aptitudes.
- Detailed Description
tDCS will be used in a sham-controlled, double-blind, randomized, cross-over control trial in MS patients suffering from cognitive impairments and/or motor deficits. After informed consent and recruitment, patients will be randomly (computer method) allocated to real or sham tDCS, that will be applied during working memory and attentional tasks. A few days/weeks after completing one arm, the patients will enter the other arm (double-blind cross-over design).
Baseline and follow-up outcomes about cognitive aptitudes, motor tasks and fatigue will be collected.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 100
- MS patients with relapsing remitting MS/secondary progression MS (based on the 2010 revised McDonald criteria)
- Cognitive deficits
- Motor deficits
- contraindication to tDCS (seizure or epilepsy, metal in the head, ...)
- major psychiatric conditions or major depression
- coexisting instable medical condition
- substance or alcohol abuse
- regular intake of drug that strongly modulate brain excitability
- major sequels from MS preventing participation in the study
- pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Sham tDCS tDCS this will be exactly as for "real tDCS" unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial) real tDCS tDCS Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes. tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks
- Primary Outcome Measures
Name Time Method Enhancement of Cognitive aptitudes with tDCS from baseline to 4 weeks after the intervention The effect of intervention on attentional, working memory and executive function deficits will be quantified by means of validated tests before and after intervention.
- Secondary Outcome Measures
Name Time Method Enhancement of Motor skills with tDCS from baseline to 4 weeks after the intervention Performance on motor skill learning tasks and on different commonly used tasks (Purdue Pegboard, hand dynamometer, pinch dynamometer, 9-HPT, motor skill learning with a videogame, ...) will be measured to explore the impact of tDCS on these parameters in MS patients' population.
Impact on Fatigue and Enhancement of Cognitive performances with tDCS from baseline to 4 weeks after the intervention The effect of intervention on fatigue and performances on the cognitive tasks will be quantified by means of validated questionnaires at inclusion and after tDCS.
Trial Locations
- Locations (1)
Department of Neurology, CHU Dinant Godinne UcL Namur
🇧🇪Yvoir, Namur, Belgium